Paradigm Capital Management Inc. NY Has $2.89 Million Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Paradigm Capital Management Inc. NY lessened its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 55.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 478,021 shares of the medical instruments supplier’s stock after selling 601,079 shares during the period. Paradigm Capital Management Inc. NY owned approximately 1.19% of AngioDynamics worth $2,892,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Quest Partners LLC bought a new position in AngioDynamics in the fourth quarter valued at approximately $69,000. RPO LLC bought a new stake in AngioDynamics in the 4th quarter valued at $83,000. AE Wealth Management LLC acquired a new position in AngioDynamics in the 2nd quarter worth $87,000. State Board of Administration of Florida Retirement System increased its holdings in AngioDynamics by 44.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares in the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in shares of AngioDynamics in the 1st quarter valued at about $106,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ANGO has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a report on Friday. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.25.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $7.50 on Tuesday. The stock has a 50 day moving average price of $7.49 and a 200 day moving average price of $6.52. The stock has a market capitalization of $300.41 million, a PE ratio of -1.55 and a beta of 0.65. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.11. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The business had revenue of $71.00 million during the quarter, compared to analysts’ expectations of $70.86 million. During the same period last year, the business earned $0.02 earnings per share. The firm’s revenue was down 22.1% on a year-over-year basis. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.